The partnership will use Debiopharm's AbYlink conjugation tech in combination with Alkyon’s modular antibody platform.

MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO, June 12, 2025--Debiopharm ( a privately-owned Swiss ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

This article explores the current landscape and future potential of cell therapies, including CAR T-cell and stem cell-based ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The research program will combine Debiopharm’s AbYlink conjugation technology with Alkyon’s modular antibody platform and ...

Figure 3: (A) Time course of antibody state. At least 90% of the antigens were capable of binding antibodies, as estimated by comparing the recognition and topography image of Figure 3B and D.

Research program combining Debiopharm's AbYlink conjugation technology with Alkyon's modular antibody platform and novel targeting approaches is set to drive next-generation targeted radiopharmaceutic ...